Cassava Sciences公司今日盘中大涨7.46%，引发了市场广泛关注。
该公司目前正在进行两项针对阿尔茨海默病患者的3期临床试验，测试其候选药物simufilam的疗效。这一进展为simufilam成为阿尔茨海默病有效治疗药物带来了期望，提振了投资者对公司前景的信心。
Cassava Sciences是一家专注于阿尔茨海默病诊疗的生物技术公司。除了simufilam外，该公司还开发了SavaDx诊断产品, 可通过血液样本检测阿尔茨海默病。随着候选产品研发进入关键阶段,公司盈利前景趋于乐观,因此股价出现大涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.